Loading
Extracellular Vesicles in Disease / Adipokines, Inflammation, and Metabolic Diseases · Journal article
Frontiers in Endocrinology · September 9, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review synthesizing existing knowledge on the mechanistic role of ceramides in adipose tissue dysfunction and their potential involvement in extracellular vesicle signalling. The article proposes frameworks linking ceramide accumulation to insulin resistance and metabolic dysregulation but presents no new primary data or quantified evidence to test these hypotheses.
Narrative review article. Individuals with obesity and metabolic dysfunction; focus on adipose tissue physiology.
Adipose tissue ceramide accumulation is proposed as a mechanism linking obesity to insulin resistance and systemic metabolic dysregulation Ceramides may modulate extracellular vesicle secretion from white adipose tissue and serve as bioactive lipid components able to differentiate metabolic status
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review identifies ceramides and extracellular vesicles as potential therapeutic targets and biomarkers for metabolic dysregulation, but readers should recognize that the mechanistic proposals require validation through prospective clinical trials or controlled experimental studies before clinical application.
This is a narrative review article that synthesizes existing literature to propose mechanisms linking adipose ceramides and extracellular vesicles to metabolic dysregulation, raising questions for investigation rather than reporting new empirical evidence.
As stated by the source record.
This review identifies ceramides and extracellular vesicles as potential therapeutic targets and biomarkers for metabolic dysregulation, but readers should recognize that the mechanistic proposals require validation through prospective clinical trials or controlled experimental studies before clinical application.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Adipose tissue dysfunction is at the interphase between obesity and impaired metabolic health. Increased lipid spillover is a key mechanism by which adipose tissue dysfunction contributes to systemic metabolic dysregulation. This, in turn, leads to the accumulation of lipotoxic lipid species, such as ceramides, within metabolically active tissue not suited for lipid storage tissues thereby fueling insulin resistance. However, the buildup of ceramides also occurs in the adipose tissue of individuals with obesity where these sphingolipids may disrupt energy metabolism, insulin sensitivity and affect adipose tissue secretome, compromising systemic metabolic health. This review will provide an updated overview on the contribution of ceramides to adipose tissue dysfunction, with a particular focus on the onset of insulin resistance. Additionally, this manuscript will focus on the involvement of ceramides in modulating extracellular vesicle (EVs) secretion from the white adipose tissue and their role as bioactive components of EV lipidome able to discern individuals based on their metabolic status.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.